The company has not filed an annual or quarterly report since its FY2021 20-F, filed Mar 10, 2022. Its latest SEC filing is a EFFECT from Aug 2, 2023.
20-F for FY2021, filed Mar 10, 2022
The sections below describe the company as of the FY2021 annual report.
Develops, manufactures and markets cardiovascular devices, including the Reducer for refractory angina and the Tiara for mitral valve disease.
20-F for FY2021, filed Mar 10, 2022Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular…View ↗
Neovasc sells the Reducer directly in Germany and France and through distributors in other European countries, the Middle East and Australia; it has distribution agreements in Saudi Arabia and Israel.
20-F for FY2021, filed Mar 10, 2022MarketingView ↗
20-F for FY2021, filed Mar 10, 2022
Sales to the Company’s three largest customers accounted for approximately 15%, 11% and 5% of the Company’s sales for the year ended…View ↗
Loading...
